Please ensure Javascript is enabled for purposes of website accessibility

Teva Pharmaceuticals Unit Actavis Generics Wins FDA Approval for Lung Cancer Drug Pemetrexed

By Eric Volkman - Aug 24, 2020 at 6:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drug is a generic form of the highly successful Alimta.

Teva Pharmaceuticals (TEVA 1.08%) has a new treatment it can market. The company's Actavis Generics unit has been granted Food and Drug Administration (FDA) approval for its Pemetrexed chemotherapy treatment, which combats lung cancer.

An injectable form of the drug has been approved as a single agent for use in patients with "locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has not progressed after four cycles of first-line platinum-based chemo[therapy]."

Cancer attacking an organism.

Image source: Getty Images.

The injection was also granted approval, again as a single agent, to treat recurrent, metastatic non-squamous NSCLC in patients who received prior chemotherapy.

Teva has not yet commented on the FDA approval. 

Pemetrexed is a generic salt form of a high-profile lung cancer drug, Alimta, which was developed and marketed by Eli Lilly (LLY 2.63%) and became a top seller for that company. It was the focus of a contentious 2014 patent case in the U.K., in which Actavis prevailed. Since then, however, Eli Lilly has won various patent infringement suits related to Alimta. Its patent expires in May 2022.

Teva acquired Actavis Generics in 2016.

In development since 2000, Alimta was first approved by the FDA in 2004, in combination with chemotherapy agent cisplatin, to treat malignant pleural mesothelioma. This is a type of cancer that affects the lining of the lungs. Alimta was the first drug to win approval for this disease.

Despite the news, Teva shares were not an investor favorite on Monday. They fell by 2.6% on the day, in contrast to the gains of the top equity indexes.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$11.21 (1.08%) $0.12
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$308.08 (2.63%) $7.89

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.